Citations (28)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Naren P Rao & Gary Remington. (2013) Investigational drugs for schizophrenia targeting the dopamine receptor: Phase II trials. Expert Opinion on Investigational Drugs 22:7, pages 881-894.
Read now
Read now
Articles from other publishers (27)
Zina Sherzad Qadir, Patrick Anthony Ball & Hana Morrissey. (2023) Efficacy and Tolerance of Antipsychotics Used for the Treatment of Patients Newly Diagnosed with Schizophrenia: A Systematic Review and Meta-Analysis. Pharmacy 11:6, pages 175.
Crossref
Crossref
Christy L M Hui, Eric Y H Chen, Verma Swapna, Hiromi Tagata, Masafumi Mizuno, Chen‑Chung Liu, Hiroyoshi Takeuchi, Sung-Wan Kim & Young-Chul Chung. (2022) Guidelines for Discontinuation of Antipsychotics in Patients Who Recover From First-Episode Schizophrenia Spectrum Disorders: Derived From the Aggregated Opinions of Asian Network of Early Psychosis Experts and Literature Review. International Journal of Neuropsychopharmacology.
Crossref
Crossref
David M. Taylor, Thomas R. E. Barnes & Allan H. Young. 2021. The Maudsley Prescribing Guidelines in Psychiatry. The Maudsley Prescribing Guidelines in Psychiatry
1
224
.
Minho Song, Jungsun Lee, Harin Kim, Soojin Ahn, Young Jae Choi, Young Tak Jo & Sung Woo Joo. (2021) Association of the First Antipsychotic Treatment Duration With the Re-Initiation of Treatment in Schizophrenia: A National Health Insurance Data-Based Study. Korean Journal of Schizophrenia Research 24:2, pages 60-67.
Crossref
Crossref
Mark Abie Horowitz, Sameer Jauhar, Sridhar Natesan, Robin M Murray & David Taylor. (2021) A Method for Tapering Antipsychotic Treatment That May Minimize the Risk of Relapse. Schizophrenia Bulletin 47:4, pages 1116-1129.
Crossref
Crossref
Alp Üçok & İlayda Arjen Kara. (2020) Relapse rates following antipsychotic discontinuation in the maintenance phase after first-episode of schizophrenia: Results of a long-term follow-up study. Schizophrenia Research 225, pages 31-38.
Crossref
Crossref
Konstantinos N. Fountoulakis, Panagiotis Panagiotidis, Antonis T. Theofilidis & Ioannis Nimatoudis. (2020) One-year Outcome of First vs. Later Episode Schizophrenia: A Real-world Naturalistic Study. Clinical Psychopharmacology and Neuroscience 18:3, pages 434-444.
Crossref
Crossref
Anna Ceraso, Jessie Jingxia LIN, Johannes Schneider-Thoma, Spyridon Siafis, Magdolna Tardy, Katja Komossa, Stephan Heres, Werner Kissling, John M Davis & Stefan Leucht. (2020) Maintenance treatment with antipsychotic drugs for schizophrenia. Cochrane Database of Systematic Reviews 2020:8.
Crossref
Crossref
Taro Kishi, Toshikazu Ikuta, Yuki Matsui, Ken Inada, Yuki Matsuda, Kazuo Mishima & Nakao Iwata. (2018)
Effect of discontinuation
v.
maintenance of antipsychotic medication on relapse rates in patients with remitted/stable first-episode psychosis: a meta-analysis
. Psychological Medicine 49:5, pages 772-779.
Crossref
Crossref
Mark Taylor & Sameer Jauhar. (2019) Are we getting any better at staying better? The long view on relapse and recovery in first episode nonaffective psychosis and schizophrenia. Therapeutic Advances in Psychopharmacology 9, pages 204512531987003.
Crossref
Crossref
Lex Wunderink. (2019) Personalizing antipsychotic treatment: evidence and thoughts on individualized tailoring of antipsychotic dosage in the treatment of psychotic disorders. Therapeutic Advances in Psychopharmacology 9, pages 204512531983656.
Crossref
Crossref
Miriam Larsen-Barr, Fred Seymour, John Read & Kerry Gibson. (2018) Attempting to discontinue antipsychotic medication: Withdrawal methods, relapse and success. Psychiatry Research 270, pages 365-374.
Crossref
Crossref
Andrew Thompson, Catherine Winsper, Steven Marwaha, Jon Haynes, Mario Alvarez-Jimenez, Sarah Hetrick, Alba Realpe, Laura Vail, Sarah Dawson & Sarah A. Sullivan. (2018) Maintenance antipsychotic treatment versus discontinuation strategies following remission from first episode psychosis: systematic review. BJPsych Open 4:4, pages 215-225.
Crossref
Crossref
Robin Emsley. (2018) Discontinuing antipsychotic treatment after a first-episode of psychosis: Who, when and how?. Schizophrenia Research 197, pages 59-60.
Crossref
Crossref
D. R. Gotfredsen, R. S. Wils, C. Hjorthøj, S. F. Austin, N. Albert, R. G. Secher, A. A. E. Thorup, O. Mors & M. Nordentoft. (2017) Stability and development of psychotic symptoms and the use of antipsychotic medication – long-term follow-up. Psychological Medicine 47:12, pages 2118-2129.
Crossref
Crossref
M. Alvarez-Jimenez, B. O’Donoghue, A. Thompson, J. F. Gleeson, S. Bendall, C. Gonzalez-Blanch, E. Killackey, L. Wunderink & P. D. McGorry. (2016) Beyond Clinical Remission in First Episode Psychosis: Thoughts on Antipsychotic Maintenance vs. Guided Discontinuation in the Functional Recovery Era. CNS Drugs 30:5, pages 357-368.
Crossref
Crossref
Mei Hung Chi, Chih Yin Hsiao, Kao Chin Chen, Lan-Ting Lee, Hsin Chun Tsai, I Hui Lee, Po See Chen & Yen Kuang Yang. (2016) The readmission rate and medical cost of patients with schizophrenia after first hospitalization — A 10-year follow-up population-based study. Schizophrenia Research 170:1, pages 184-190.
Crossref
Crossref
Wolfgang Gaebel, Mathias Riesbeck, Wolfgang Wölwer, Ansgar Klimke, Matthias Eickhoff, Martina von Wilmsdorff, Walter de Millas, Wolfgang Maier, Stephan Ruhrmann, Peter Falkai, Heinrich Sauer, Andrea Schmitt, Michael Riedel, Stefan Klingberg & Hans-Jürgen Möller. (2016) Predictors for symptom re-exacerbation after targeted stepwise drug discontinuation in first-episode schizophrenia. Schizophrenia Research 170:1, pages 168-176.
Crossref
Crossref
Marc De Hert, Jan Sermon, Paul Geerts, Kristof Vansteelandt, Joseph Peuskens & Johan Detraux. (2015) The Use of Continuous Treatment Versus Placebo or Intermittent Treatment Strategies in Stabilized Patients with Schizophrenia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials with First- and Second-Generation Antipsychotics. CNS Drugs 29:8, pages 637-658.
Crossref
Crossref
Hannah Steeds, Robin L. Carhart-Harris & James M. Stone. (2014) Drug models of schizophrenia. Therapeutic Advances in Psychopharmacology 5:1, pages 43-58.
Crossref
Crossref
Sofia Brissos, Miguel Ruiz Veguilla, David Taylor & Vicent Balanzá-Martinez. (2014) The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal. Therapeutic Advances in Psychopharmacology 4:5, pages 198-219.
Crossref
Crossref
Robin Emsley, Bonginkosi Chiliza, Laila Asmal, Stefan du Plessis, Lebogang Phahladira, Evette van Niekerk, Susan J. van Rensburg & Brian H. Harvey. (2014) A randomized, controlled trial of omega-3 fatty acids plus an antioxidant for relapse prevention after antipsychotic discontinuation in first-episode schizophrenia. Schizophrenia Research 158:1-3, pages 230-235.
Crossref
Crossref
Robert B. Zipursky, Natasja M. Menezes & David L. Streiner. (2014) Risk of symptom recurrence with medication discontinuation in first-episode psychosis: A systematic review. Schizophrenia Research 152:2-3, pages 408-414.
Crossref
Crossref
Robin Emsley, Bonginkosi Chiliza, Laila Asmal & Brian H Harvey. (2013) The nature of relapse in schizophrenia. BMC Psychiatry 13:1.
Crossref
Crossref
Robert B. Zipursky, Thomas J. Reilly & Robin M. Murray. (2013) The Myth of Schizophrenia as a Progressive Brain Disease. Schizophrenia Bulletin 39:6, pages 1363-1372.
Crossref
Crossref
Stefan Leucht, Magdolna Tardy, Katja Komossa, Stephan Heres, Werner Kissling, Georgia Salanti & John M Davis. (2012) Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. The Lancet 379:9831, pages 2063-2071.
Crossref
Crossref
Stefan Leucht, Magdolna Tardy, Katja Komossa, Stephan Heres, Werner Kissling & John M Davis. (2012) Maintenance treatment with antipsychotic drugs for schizophrenia. Cochrane Database of Systematic Reviews.
Crossref
Crossref